- Home
- STAI vs MIRA Comparison
STAI vs MIRA Comparison
Compare STAI & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- MIRA
- Stock Information
- Founded
- STAI 2011
- MIRA 2020
- Country
- STAI United States
- MIRA United States
- Employees
- STAI N/A
- MIRA N/A
- Industry
- STAI
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- MIRA Health Care
- Exchange
- STAI Nasdaq
- MIRA Nasdaq
- Market Cap
- STAI 24.6M
- MIRA 33.7M
- IPO Year
- STAI N/A
- MIRA 2023
- Fundamental
- Price
- STAI $0.50
- MIRA $1.67
- Analyst Decision
- STAI
- MIRA
- Analyst Count
- STAI 0
- MIRA 0
- Target Price
- STAI N/A
- MIRA N/A
- AVG Volume (30 Days)
- STAI 14.9M
- MIRA 8.9M
- Earning Date
- STAI 09-17-2025
- MIRA 11-14-2025
- Dividend Yield
- STAI N/A
- MIRA N/A
- EPS Growth
- STAI N/A
- MIRA N/A
- EPS
- STAI N/A
- MIRA N/A
- Revenue
- STAI $1,249,524.00
- MIRA N/A
- Revenue This Year
- STAI N/A
- MIRA N/A
- Revenue Next Year
- STAI N/A
- MIRA N/A
- P/E Ratio
- STAI N/A
- MIRA N/A
- Revenue Growth
- STAI 139.30
- MIRA N/A
- 52 Week Low
- STAI $0.35
- MIRA $0.73
- 52 Week High
- STAI $9.07
- MIRA $2.45
- Technical
- Relative Strength Index (RSI)
- STAI 48.16
- MIRA 60.28
- Support Level
- STAI $0.48
- MIRA $1.57
- Resistance Level
- STAI $0.73
- MIRA $1.80
- Average True Range (ATR)
- STAI 0.07
- MIRA 0.18
- MACD
- STAI -0.01
- MIRA 0.02
- Stochastic Oscillator
- STAI 8.74
- MIRA 35.00
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.